A new large - scale
cell and gene therapy manufacturing centre is scheduled to open in early 2018 in Stevenage, Hertfordshire.
First hand experience of implementing automated solutions across
the cell and gene therapy manufacturing pathway.
Not exact matches
Dr. Levine directs the Clinical
Cell and Vaccine Production Facility (CVPF), which develops, manufactures, and tests novel cell and gene therapies in clinical trials at Penn and collaborating instituti
Cell and Vaccine Production Facility (CVPF), which develops,
manufactures,
and tests novel
cell and gene therapies in clinical trials at Penn and collaborating instituti
cell and gene therapies in clinical trials at Penn
and collaborating institutions.
Supported by: Hear from leading expert Dr David DiGiusto, Stanford University School of Medicine, USA, as he shares his extensive experience in developing
and optimizing
manufacturing processes for
cell and gene therapy products including:
The remainder of the webinar is a Q&A session with both Dr DiGiusto
and Dr Schlinker sharing their perspective on the critical issues around
manufacture of
cell and gene therapies.
Native viral vectors can be therapeutics themselves, but they also function as a critical input to
manufacturing rapidly emerging therapeutic platforms, including CAR - T
and other forms of
gene - modified whole -
cell therapies.